Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XTAMPZA ER vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Mild to moderate pain,Fever
Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
3-4 hours for immediate-release morphine; 8-12 hours for extended-release formulation (XTAMPZA ER), allowing twice-daily dosing
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via CYP3A4 and CYP2D6 to active and inactive metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (70-90% as morphine-3-glucuronide, morphine-6-glucuronide, and free morphine); biliary/fecal (10-20%)
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
20-35% bound to albumin
Approximately 10-20% bound to serum albumin; extensive tissue binding.
1-4 L/kg; high Vd indicates extensive tissue distribution (muscle, kidney, liver, lungs)
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 30-40% (first-pass metabolism reduces systemic availability; XTAMPZA ER uses Cydot technology to enhance absorption and reduce food effect)
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-59 m L/min: reduce dose by 25% and titrate cautiously; GFR <30 m L/min: contraindicated or avoid use due to accumulation of naltrexone metabolite.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A or B: no adjustment recommended; Child-Pugh Class C: avoid use (no studies).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for patients <18 years of age.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Start at low end of dosing range (9 mg every 12 hours); titrate slowly due to increased sensitivity and potential for respiratory depression.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; opioid risk evaluation and mitigation strategy (REMS).
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Opioid-induced hyperalgesia,Gastrointestinal effects (e.g., constipation, ileus),Adrenal insufficiency,Severe hypotension,Seizures,Use in patients with increased intracranial pressure or head injury
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to oxycodone or any component of the formulation
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase oxycodone levels, potentiating toxicity. High-fat meals may delay absorption but do not alter overall exposure significantly. Alcohol should be strictly avoided as it can increase CNS depression and risk of respiratory depression.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy category C. First trimester: Potential for neural tube defects and other major malformations, though data limited. Second and third trimesters: Prolonged use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Risk of preterm labor, low birth weight, and fetal growth restriction with chronic use.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in human milk; M/P ratio not reported. Monitor infant for respiratory depression, sedation, and withdrawal symptoms. Use caution, especially with high maternal doses or prolonged use. Breastfeeding generally not recommended due to risk of infant toxicity.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy may alter pharmacokinetics due to increased hepatic metabolism, renal clearance, and plasma volume expansion. Lower AUC and Cmax expected; consider dose adjustments based on pain severity, but avoid abrupt discontinuation to prevent withdrawal. No standard dose recommendations; titrate to effect with caution.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
XTAMPZA ER is an extended-release formulation of oxycodone designed to be taken once daily. It uses a polymer matrix to provide prolonged absorption. Do not crush, chew, or dissolve the capsules, as this can lead to rapid release and potential fatal overdose. Due to its high drug load, it is not interchangeable with other oxycodone ER products. Initiate with caution in opioid-naive patients; consider lower starting doses. Monitor for respiratory depression, especially during initiation and titration. Use with CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) requires dose adjustment. Abuse-deterrent properties are limited; caution in patients with history of substance abuse.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Swallow the capsule whole; do not crush, chew, or dissolve it.,Avoid alcohol while taking this medication; it can increase the risk of dangerous side effects.,Do not stop abruptly; work with your doctor to taper the dose to avoid withdrawal symptoms.,Store safely out of reach of children and pets; dispose of unused medication via a take-back program.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Report any breathing difficulty, severe constipation, or signs of overdose (e.g., extreme sleepiness, slow heartbeat).
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XTAMPZA ER vs ACEPHEN, answered by our medical review team.
XTAMPZA ER is a Opioid Analgesic that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XTAMPZA ER and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XTAMPZA ER is: Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XTAMPZA ER and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XTAMPZA ER is classified as Category C. Pregnancy category C. First trimester: Potential for neural tube defects and other major malformations, though data limited. Second and third trimesters: Prolonged use may lead to . ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.